Skip to main content

Novartis to begin trials for meningitis vaccine


NEW YORK Novartis will soon begin clinical trials of a vaccine for meningitis B.

The vaccine could provide protection against most of the 260 bacteria strains that cause the disease, which can kill a child within a day by brain and spine inflammation.

According to Datamonitor, the vaccine could earn Basel, Switzerland-based Novartis $2 billion a year within eight years.

This ad will auto-close in 10 seconds